Download - Rubella and Rubella Vaccine
![Page 1: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/1.jpg)
Rubella and Rubella Vaccine
Epidemiology and Prevention of Vaccine-Preventable Diseases
National Immunization ProgramCenters for Disease Control and Prevention
Dr Esteghamati EPI Manager
![Page 2: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/2.jpg)
Rubella
• From Latin meaning "little red"
• Discovered in 18th century - thought to be variant of measles
• First described as distinct clinical entity in German literature
• Congenital rubella syndrome described by Gregg in 1941
![Page 3: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/3.jpg)
Rubella Virus
• Togavirus
• RNA virus
• One antigenic type
• Rapidly inactivated by chemical agents, low pH, heat and ultraviolet light
![Page 4: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/4.jpg)
Rubella Pathogenesis
• Respiratory transmission of virus
• Replication in nasopharynx and regional lymph nodes
• Viremia 5-7 days after exposure with spread to tissues
• Placenta and fetus infected during viremia
![Page 5: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/5.jpg)
Rubella Clinical Features
• Incubation period 14 days (range 12-23 days)
• Prodrome of low grade fever
• Lymphadenopathy in second week
• Maculopapular rash 14-17 days after exposure
![Page 6: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/6.jpg)
Rubella Complications
Arthralgia or arthritischildrenadult female
Thrombocytopenic purpuraEncephalitisNeuritisOrchitis
rareup to 70%
1/3000 cases
1/6,000 casesrarerare
![Page 7: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/7.jpg)
Congenital Rubella Syndrome
• Infection may affect all organs
• May lead to fetal death or premature delivery
• Severity of damage to fetus depends on gestational age
• Up to 85% of infants affected if infected during first trimester
![Page 8: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/8.jpg)
Congenital Rubella Syndrome (CRS)
![Page 9: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/9.jpg)
Congenital Rubella Syndrome
• Deafness
• Cataracts
• Heart defects
• Microcephaly
• Mental retardation
• Bone alterations
• Liver and spleen damage
![Page 10: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/10.jpg)
CRS case definitions (1)
Suspected CRS: A child <1 year with
• maternal history of rubella in pregnancy
and/or
• heart disease, or deafness, or eye signs:
white pupil (cataract); diminished vision; pendular eye movement (nystagmus); squint; smaller eye ball (micropthalmos);larger eye ball (congenital glaucoma)
![Page 11: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/11.jpg)
CRS case definitions (2)
Clinically confirmed CRS: A child <1 year with two complications in group (a) or
one from (a) and one from (b)
(a) cataract(s), congenital glaucoma, congenital heart disease, loss of hearing, pigmentary retinopathy
(b) purpura, splenomegaly, microcephaly, mental retardation, meningoencephalitis, radiolucent bone disease, jaundice with onset within 24 hours after birth.
![Page 12: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/12.jpg)
CRS case definitions (3)
Laboratory-confirmed CRS:
An infant with a positive blood test for rubella-specific IgM and clinically-confirmed CRS.
Congenital rubella infection (CRI):
An infant with a positive blood test for rubella-specific IgM who does not have clinically-confirmed CRS.
![Page 13: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/13.jpg)
TOP PRIORITY: Use rubella vaccine to prevent CRS
• To prevent CRS iTo prevent CRS introduce rubella vaccine for ntroduce rubella vaccine for women of childbearing agewomen of childbearing age
• Define age of target group
– consider local fertility rates
• Where to offer vaccine
– postpartum and family planning
– mass campaigns (Cuba, Malaysia)
![Page 14: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/14.jpg)
Epidemic Rubella – United States, 1964-1965
• 12.5 million rubella cases
• 2,000 encephalitis cases
• 11,250 abortions (surgical/spontaneous)
• 2,100 neonatal deaths
• 20,000 CRS cases–Deaf - 11,600–Blind - 3,580–Mentally retarded - 1,800
![Page 15: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/15.jpg)
Rubella Laboratory Diagnosis
• Isolation of rubella virus from clinical specimen (e.g., nasopharynx, urine)
• Significant rise in rubella IgG by any standard serologic assay (e.g., enzyme immunoassay)
• Positive serologic test for rubella IgM antibody
![Page 16: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/16.jpg)
Rubella Epidemiology
• Reservoir Human
• Transmission RespiratorySubclinical cases may
transmit
• Temporal pattern Peak in late winter and spring
• Communicability 7 days before to 5-7 daysafter rash onsetInfants with CRS may shedvirus for a year or more
![Page 17: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/17.jpg)
0
10000
20000
30000
40000
50000
60000
70000
1966 1970 1974 1978 1982 1986 1990 1994 1998 2002
Ru
bel
la C
ases
0
10
20
30
40
50
60
70
80
CR
S C
ases
Rubella CRS
Rubella - United States, 1966-2002
![Page 18: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/18.jpg)
0
500
1000
1500
20002500
3000
3500
4000
4500
1980 1985 1990 1995 2000
Ru
bel
la C
ases
0
5
10
15
20
25
30
35
40
CR
S C
ases
Rubella CRS
Rubella - United States, 1980-2002
![Page 19: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/19.jpg)
0
10
20
30
40
50
60
70
80
90
100
1980 1985 1990 1995 2000
Per
cen
tRubella - United States, 1980-2002
Age Distribution of Reported Cases
<5 yrs
15-39 yrs
>40 yrs
5-14 yrs
![Page 20: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/20.jpg)
Rubella and CRS in the United States
• Most reported rubella in the U.S. since the mid-1990s has occurred among foreign-born Hispanic adults
• Rubella outbreaks have occurred in workplaces where most employees are foreign-born
• Majority of CRS since 1997 occurred in children of unvaccinated women born to Hispanic women, most born in Latin America
![Page 21: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/21.jpg)
Rubella Case Definition
• Acute onset of generalized maculopapular rash, and
• Temperature of >37.2 C (>99 F), if measured, and
• Arthralgia or arthritis, or lymph-adenopathy, or conjunctivitis
![Page 22: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/22.jpg)
Rubella Outbreak Control Guidelines
• Laboratory diagnosis of rubella and CRS
• Step-by-step guidelines on evaluation and management of outbreak
• Rubella prevention and control among women of childbearing age
• Rubella and CRS surveillanceMMWR 2001;50(RR-12)
![Page 23: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/23.jpg)
VaccineGMK-3:RK53
HPV-77:DK12
HPV-77:DE5
RA 27/3*
Trade Name Cendevax
Rubelogen
Meruvax
Meruvax II
Licensure1969
1969
1969
1979
*Only vaccine currently licensed in U.S.
Rubella Vaccine
![Page 24: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/24.jpg)
Rubella Vaccine
• Composition Live virus (RA 27/3 strain)
• Efficacy 95% (Range, 90%-97%)
• Duration ofImmunity Lifelong
• Schedule >1 Dose
• Should be administered with measles and mumps as MMR
![Page 25: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/25.jpg)
Rubella Vaccine (MMR) Indications
• All infants >12 months of age
• Susceptible adolescents and adults without documented evidence of rubella immunity
• Emphasis on non-pregnant women of childbearing age, particularly those born outside the U.S.
![Page 26: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/26.jpg)
Rubella Immunity
• Documentation of one dose of rubella-containing vaccine on or after the first birthday
• Serologic evidence of immunity
• Birth before 1957 (except women of childbearing age)
![Page 27: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/27.jpg)
• Birth before 1957 is not acceptable evidence of rubella immunity for women who might become pregnant
• Only serology or documented vaccination should be accepted
Rubella Immunity
![Page 28: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/28.jpg)
MMR Adverse Reactions
• Fever 5%-15%
• Rash 5%
• Joint symptoms 25%
• Thrombocytopenia <1/30,000 doses
• Parotitis rare
• Deafness rare
• Encephalopathy <1/1,000,000 doses
![Page 29: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/29.jpg)
Rubella Vaccine Arthropathy
• Acute joint symptoms in about 25% of susceptable adult women
• Frank arthritis occurs in about 10%
• Rare reports of chronic or persistent symptoms
• Population-based studies have not confirmed association
![Page 30: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/30.jpg)
• Severe allergic reaction to vaccine
component or following prior dose
• Pregnancy
• Immunosuppression
• Moderate or severe acute illness
• Recent blood product
MMR VaccineContraindications and Precautions
![Page 31: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/31.jpg)
Vaccination of Women of Childbearing Age
• Ask if pregnant or likely to become so in next 4 weeks
• Exclude those who say "yes"
• For others– Explain theoretical risks– Vaccinate
![Page 32: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/32.jpg)
Vaccination in Pregnancy Study 1971-1989
• 321 women vaccinated
• 324 live births
• No observed CRS
• 95% confidence limits 0%-1.2%
![Page 33: Rubella and Rubella Vaccine](https://reader035.vdocument.in/reader035/viewer/2022081503/56813a1d550346895da1f774/html5/thumbnails/33.jpg)
Rubella VaccineRecommendations for Increasing Coverage
• Continued routine vaccination of children at age >12 months with vaccination required for school entry
• Screen and vaccinate susceptible persons– healthcare workers– college entry– prenatal with postpartum vaccination– other healthcare visits– workplace